Introduction
Converging lines of evidence indicate that depression associ ated with medical illness or immunotherapy may develop as a result of the actions of cytokines and inflammatory medi ators in the brain. [1] [2] [3] [4] A key mechanism linking the immune system with mood appears to be the activation of the enzyme indoleamine2,3dioxygenase (IDO) and the resultant en hanced conversion of the amino acid tryptophan (TRP) to kynurenine and its neurotoxic downstream metabolites, the free radical generator 3hydroxykynurenine (3HK) and the Nmethyldaspartate (NMDA) receptor agonist quinolinic acid (QUIN). [5] [6] [7] [8] [9] [10] [11] Together with kynurenic acid (KYNA), a neuro inhibitory and neuroprotective metabolite that is formed in a side arm of the kynurenine pathway (KP) of TRP degrada tion and targets a variety of receptors, 12 these mainly glia derived compounds may modulate glutamatergic neurotrans mission, [13] [14] [15] which is involved in mood disorders. 16 Supporting evidence linking the KP to depression stems from clinical studies showing that a number of patients receiving cytokine therapy experience changes in mood that correlate with re duced levels of TRP and increased levels of kynurenine and J Psychiatry Neurosci QUIN in the circulation. 17, 18 Taken together with reports of in creased levels of cytokines and other markers of inflamma tion in the blood of depressed individuals, 19, 20 these lines of evidence have led to the hypothesis that the pathophysiology of depression, in the absence of an overt inflammatory pro cess, may be related to a subsyndromal activation of the im mune system, resulting in chronic stimulation of the KP and altered glutamatergic activity. 3, 8, 9 Currently, the evidence implicating enhanced KP metab olism in depressed individuals in the absence of immunother apy or medical illness is both limited and inconsistent. Whereas several studies that were performed using specimens from blood or cerebrospinal fluid (CSF) have reported a positive as sociation between various components of the KP and depres sion or suicide, [21] [22] [23] [24] others failed to do so 25, 26 or have revealed qualitatively different changes for various analytes. 27 Moreover, evidence for abnormal brain tissue levels of KP metabolites in depressed individuals and individuals who died by suicide is limited or indirect. [28] [29] [30] The possible role of the KP in the patho physiology of depression therefore requires further clarification.
In the present study, we conducted a postmortem analysis of KP metabolite levels and the expression of KP enzymes in the ventrolateral prefrontal cortex (VLPFC) of control and de pressed individuals whose deaths had resulted from suicide or other causes. In parallel, we examined relevant neuroin flammatory markers, including cytokine gene expression, in the same tissues. The VLPFC was selected because it shows distinct abnormalities in individuals with depressive ill ness, [31] [32] [33] in particular increased glucose utilization during TRP depletion. 34 Moreover, postmortem studies have consis tently shown neurochemical evidence of serotonergic hypo function in victims of suicide. [35] [36] [37] We hypothesized that de pressed individuals would display an inflammatory profile characterized by increased cytokine expression that would correlate with increased KP activity. Results of the present study did not confirm our assumptions.
Methods

Human postmortem brain samples
The study was reviewed and approved by the Institutional Re view Board of the University of Maryland School of Medicine. Samples were obtained from the Section on Neuropathology, Clinical Brain Disorders Branch, National Institute of Mental Health (NIMH). Two boardcertified psychiatrists (J.E.K. and T.M.H.) confirmed the diagnosis and classification of depres sive disorders based on a review of the medical records and interviews with next of kin. The samples came from a total of 104 individuals, corresponding to 51 nonpsychiatric controls and 53 individuals who had a diagnosis of depressive disorder not otherwise specified (DDNOS), 26 of whom died by sui cide. Individuals with an additional diagnosis of psychotic or bipolar disorders were not included in the sample. For statis tical comparisons, we applied the following exclusion criteria: a medical condition of recognized immune involvement, such as cancer, diabetes, infection, asthma, thyrotoxicosis and neuro logic disorders (n = 19: 14 controls and 5 depressed); a pH lower than 6.0 (n = 2: 1 control and 1 depressed); and missing key data (n = 2: 1 with manner of death undetermined and 1 missing age at death). This resulted in a sample set from 81 individuals, corresponding to 36 controls and 45 who had DDNOS. Information on demographic characteristics; tissue characteristics; manner of death; and confounders, including smoking, ethanol at death and death by accidental overdose, are summarized in Table 1 . Special consideration was given to cause of death related to cardiovascular diseases (CVDs), such as heart attack, owing to their known association with inflam mation. These cases are commonly used as controls in post mortem studies of suicide owing to the sudden death and short agonal state. We conducted exploratory analyses of sub groups defined by the presence or absence of potential con founders to assess, within the limits of the available data, whether they might alter those significant differences in KP or cytokine measures found in adjusted regressions.
Tissue processing
All samples consisted of blocks of frozen tissues of at least 2 × 2 × 1 cm corresponding to the VLPFC (approximately Brod mann areas 45 and 47) spanning at least 2 gyri and 2 sulci and containing both grey and white matter. Serial consecu tive sections 20 µm thick were used for histochemistry or col lected for reverse transcriptase-polymerase chain reaction (RTPCR) determinations. We dissected adjacent tissue con taining grey and white matter for highperformance liquid chromatography (HPLC) and gas chromatography/mass spectrometry (GC/MS) determination of KP metabolites. Prior to analysis, all tissues were stored at -80°C. 
Real-Time RT-PCR
Total RNA was isolated from approximately 100 mg of frozen brain tissue using TRIzol (Thermo Fisher Scientific). Quantification and quality of the extraction is detailed in Appendix 1, available at jpn.ca. We reversetranscribed 500 ng of total RNA per sample into complementary DNA (cDNA) in a 20 mL reaction volume using the iScript cDNA Synthesis Kit (BioRad). The realtime PCR reaction was run on a MyiQ instrument (BioRad) with a 3step cycling program, as described previously. 38 Specific primer sets (Appendix 1, Table S1 ) were used under the same ampli fication condition, and relative expression was determined using the 2 DDCt method with multiple control genes for normalization 39 (Appendix 1).
KYNA and 3-HK determination
We analyzed KYNA and 3HK using HPLC, and they were detected fluorometrically and electrochemically, 13 respec tively (Appendix 1).
TRP, kynurenine and QUIN measurement
We quantified tryptophan, kynurenine and QUIN levels in the brain with GC/MS using a 7890A GC coupled to a 7000 MS/ MS (Agilent Technologies), using electron capture negative chemical ionization as described previously 40 (Appendix 1).
Histology and immunohistochemistry
Serial consecutive sections were processed for microscopic histological analyses using Nissl and Hematoxylin and Eosin staining for the assessment of vascular integrity and verifica tion of the absence of peripheral cell infiltration. We used acidic toluidine blue to detect mast cells and corpora amyla cea, indicative of dead astrocytes and normal aging pro cesses. Sections were also processed for ionized calcium binding adapter (IBA1) immunohistochemistry using the nickelDAB method for enhanced detection. 41 Microscopic examination and semiquantification was carried out as de scribed in the supplemental methods and in Figures S1 and S2 of Appendix 1.
Statistical analyses
We logtransformed KP analytes and mRNA expression data to approximate normal distributions. We compared de pressed and control groups using the transformed variables with analysis of covariance (ANCOVA). Covariates selected for inclusion in these models included age, sex and postmor tem interval (PMI) as a marker of tissue quality. Tissue pH was considered for inclusion, but excluded owing to very low variability among the samples selected for this study. Age and sex were selected for potential biological relevance to the processes under study. Adjusted means were back transformed (exponentiated) to yield geometric means with asymmetric 95% confidence intervals (CIs). False discovery rates for statistical multiple comparison tests were controlled using the Benjamini-Hochberg modification of the Bonfer roni procedure. 42 We used a second approach involving the Wilcoxon rank sum test of nontransformed, unadjusted data to confirm our results. Exploratory analyses were conducted to examine the distribution of KP metabolites and enzyme activity and of in flammatory cytokines in subgroups defined by variables un evenly distributed between the depressed and control groups or for which information was not completely available (i.e., alcohol at the time of death, death by overdose and death re lated to a cardiovascular event). All analyses were conducted with either SAS software version 9.3 (SAS Institute Inc.) or STATA software (StataCorp LP).
Results
Kynurenine formation is reduced in the VLPFC of depressed individuals
Age at death, pH and PMI did not differ significantly be tween the control and depressed groups (Table 1) , and none of these parameters correlated with any of the outcome meas ures analyzed, including KP metabolites and cytokines. All linear regression models comparing geometric means for de pressed and control individuals were adjusted for age at death, PMI and race.
We found significant differences between control and de pressed individuals for the adjusted means of the kynurenine:TRP ratio (0.045 v. 0.038, t 74 = 2.41, p = 0.019; Fig. 1A ) and for QUIN levels (1.59 v. 1.11, t 74 = 2.46, p = 0.016; Table 2 ), with the depressed group displaying lower non adjusted values. No significant differences between adjusted means of control and depressed individuals were found for either TRP or kynurenine. We observed lower values for KYNA and 3HK levels in the depressed group, but these re ductions were not significant (Table 2 ). Finally, no significant effect of sex was detected when comparing controls with de pressed individuals for any of the KP metabolites measured.
Significant differences were also found for mRNA levels of the enzymes IDO1 (0.96 v. 0.40, t 68 = 4.39, p < 0.001), IDO2 (0.84 v. 0.40, t 59 = 2.95, p < 0.001) and tryptophan2,3 dioxygenase (TDO2; 0.92 v. 0.37, t 68 = 4.39, p < 0.001; Table 2 ). The reduced kynurenine:TRP ratio in the depressed group indicates a decreased conversion of TRP into kynurenine and is in agreement with the lower expression of the IDO1, IDO2 and TDO2 genes.
Reduced cytokine mRNA expression in the VLPFC of depressed individuals
We found significant differences in mRNA expression be tween control and depressed individuals, with higher values in controls, for the cytokines tumour necrosis factor (TNF)α Table 3 ). No differences be tween groups were observed for the expression of the cytokines IL1β, IL6, IL4 and IL5, and for the enzyme cyclooxygenase2 (COX2). These results indicate that, overall, depressed indi viduals showed reduced mRNA expression levels in some of the cytokines analyzed in the VLPFC when compared with nonpsychiatric controls.
Correlation analyses
Pearson's correlation coefficients of logtransformed values showed that mRNA levels for the cytokines IFNγ, TNFα IL13 and IL33 had the strongest correlations with a majority of the KP measures analyzed in the combined data from con trols and depressed individuals (Table 4) . Both IFNγ and TNFα correlated with the kynurenine:TRP ratio (r = 0.32 and r = 0.38, respectively) and with mRNA expression of the en zymes IDO1, IDO2 and TDO2 (Table 4 ). In the overall sam ple, we found positive correlations for the kynurenine:TRP ratio and the expression of IDO1 (r = 0.36, p = 0.001), IDO2 (r = 0.34, p = 0.029) and TDO2 (r = 0.32, p = 0.028; Appendix 1, Table S2 ). Significant and positive correlations also existed between kynurenine and all of its measured metabolites (3 HK: r = 0.54; QUIN: r = 0.61; KYNA: r = 0.50) as well as be tween the levels of KYNA, 3HK and QUIN. These positive correlations between the kynurenine:TRP ratio and the ex pression of the converting enzymes support the accuracy and consistency of the biochemical and RTPCR determinations and indicate that the main effect is driven by a reduced enzy matic conversion of TRP to kynurenine, which is likely a con sequence of decreased IDO1, IDO2 and TDO2 expression in depressed individuals.
Subgroup analyses
We conducted subgroup comparisons of variables showing significant differences in the main analyses. These included the kynurenine:TRP ratio, QUIN, IDO1, IDO2, TDO2 and the cytokines IFNγ, TNFα, IL13, IL33 and CCL2. Subgroup analyses were performed for manner of death (suicide v. nonsuicide) in the depressed group and for groups defined by potential confounders (e.g., accidental overdose v. other causes of death, death from CVDs v. accident/homicide) in the control and depressed groups; additional subgroup com parisons are described in Appendix 1. To explore additional potential confounders, we also performed unadjusted group and subgroup comparisons using Wilcoxon ranksum tests for nontransformed data. Similar to the results of our linear regression models, we found statistically significant differ ences between depressed individuals and controls for the kynurenine:TRP ratio (z 1 = 2.44, p = 0.015; Fig. 1A ) and for QUIN levels (z 1 = 2.56, p = 0.009; Appendix 1, Fig. S3 ). Sub group comparisons for the kynurenine:TRP ratio showed no significant differences between depressed individuals who died by suicide versus other causes (Fig. 1B) , between de pressed individuals who died by overdose versus nonover dose (Fig. 1C) , or in ethanol at the time of death (Fig. 1D) , or between depressed individuals who died from CVD events versus other causes (Fig. 1E) and controls who died from CVD versus accident/homicide (Fig. 1F) . Similarly, no sub group differences were found for QUIN and the enzymes IDO1, IDO2 and TDO. Additional subgroup comparisons for cytokines showed no significant differences. Since informa tion on antidepressant medications was incomplete in the de pressed sample, we assessed the effects of fluoxetine on KP metabolites in the cerebral cortex of rats under chronic ad ministration. We found no effect on any KP metabolite after 21 days of fluoxetine treatment (Appendix 1, Table S3 ). 
Histopathology and immunohistochemistry
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corresponding to less than 5% of the total microglial popula tion for controls and less than 9% for depressed individuals. We identified no specific anatomic distribution when com paring grey versus white matter, and no differences between depressed individuals who died by suicide versus other causes were observed. Intensely stained hypertrophic micro glia, characterized by long, thick hyperramified processes, were primarily restricted to the boundaries between the ner vous tissue and vascular and meningeal regions (Appendix 1, Fig. S2D ). These conspicuous microglia were observed in 24 of 36 controls (67%) and in 29 of 47 depressed individuals (62%), with no differences between groups or correlations with any of the markers assessed in the present study. In line with the KP and cytokine data obtained in these samples, our results confirmed the absence of an overt M1 type of pro inflammatory process in adjacent tissue.
Discussion
Contrary to our expectations, the kynurenine:TRP ratio as well as QUIN levels and the expression of major KP enzymes were significantly decreased in the VLPFC of depressed indi viduals compared with nonpsychiatric controls. The expres sion of TNFα, IFNγ and other proinflammatory cytokines was also unexpectedly reduced in this brain region. Parallel microscopic analyses revealed that none of the depressed in dividuals had evidence of overt, ongoing inflammatory pro cesses. A small increase in amoeboid, probably phagocytic, microglial cells in the VLPFC of depressed individuals was not deemed pathological, as the density of these cells was very low. Notably, all these abnormalities were independent of the cause of death. Statistical analyses showed that several components of the KP correlated both with each other and with markers of inflammation in both controls and depressed individuals. These findings confirm the existence of biochem ical links between immune factors and KP metabolism in the human brain, but also highlight the heterogeneity of depres sive illness and indicate that, in the VLPFC, immune activa tion by a classical proinflammatory M1 type of response does not appear to be part of disease pathology. The VLPFC is part of the orbitofrontal cortex region, which is involved in higher emotional function 33 and is considered a critical neural substrate in the pathology of depression. 31, 32 Postmortem studies in this region have shown reductions in serotonin transporter function associated with a loss of sero tonergic terminals, concurrent with a presumably compen satory increase in serotonin receptor binding in individuals who died by suicide, suggesting reduced serotonergic activ ity. 35, 36 This serotonergic hypofunction was associated with increased impulsivity and impaired decisionmaking preceding suicidal behaviour. 35 Remarkably, the metabolic activity of the lateral portions of the orbitofrontal area, in cluding the VLPFC, was previously found to be negatively correlated with depression severity 31, 33 and to be specifically affected during a TRP depletion (TD) test in depressed indi viduals. 34 Interestingly, while the protocol of inducing TD likely results in reduced levels of serotonin in the brain, there is a consensus that TD involves other mechanisms as well. 43 It is possible that reductions in KP metabolites during TD 44 also contribute to VLPFC dysfunction and the manifestation of depressive symptomatology.
Increased formation of kynurenine and downstream KP metabolites has been repeatedly described in the blood and CSF of individuals suffering from depressive disorders and suicide attempters. [21] [22] [23] 45 Nevertheless, this has not been con sistently reported in the literature, 25, 26, 46, 47 and changes in KP metabolites and their corresponding enzymes in human se rum and CSF do not necessarily parallel events in the brain.
14 Furthermore, to our knowledge only 2 groups had examined the KP in postmortem brains of individuals with depressive illnesses prior to the present study. In the anterior cingulate cortex (ACC), 1 group reported a higher density of TDO positive glial cells in depressed individuals compared with controls 29 but revealed no change in the tissue levels of several KP metabolites, 28 whereas the other investigators described subregionspecific changes in the density of QUINpositive microglial cells in depressed individuals. 30, 48 The present study, which revealed a reduction rather than an increase in brain KP metabolism in depressed individuals, indicates that an etiological link between enhanced KP metabolism and de pression does not appear to exist in the absence of overt signs of inflammatory processes in the VLPFC. Taken together, these studies and ours strongly suggest that regulation of the KP in the human brain may be regionspecific and that the consequence of compensatory mechanisms between different brain regions is affected in individuals with depression.
Although the expression of pro and antiinflammatory cy tokines and immune markers in the brain has often been re ported as increased in individuals with depression and sui cidality, the results from different brain repositories and laboratories have been quite inconsistent in this respect. 38, [49] [50] [51] [52] [53] A previous study from our group reported increased expres sion of IL4 and IL13, and no differences in IL6, TNFα and IL1β, in the orbitofrontal cortex of individuals who died by suicide compared with controls. 38 This variability in the ex pression of certain cytokines in the brain suggests that cau tion is indicated regarding their use as biological markers of mood disorders. Future clarification of the association be tween brain inflammatory markers and depressive illness should carefully consider diagnostic subgroups based on variables affecting inflammation, such as body mass index, nutritional status and sleep.
The unexpected results in the present study may be attrib utable to a number of different factors. The most obvious ex planation is that the specific brain region studied and/or the diagnosis classification of the depressed sample influenced the overall results. Whereas our study focused on the VLPFC, most postmortem studies that have reported increased cyto kine expression in depressed individuals and individuals who died by suicide were conducted in other areas of the brain, including different regions of the prefrontal cortex (PFC). 49, 51, 53 Additionally, the diagnosis of DDNOS, while prevalent among the general population, 54 constitutes a het erogeneous category of depressive disorders. Alternatively, considering that depression is not uniform, the results of this study may be dependent on the distribution of proinflam matory and nonproinflammatory depressive phenotypes in our sample set. Finally, a reassessment of the association be tween the KP, inflammation and depression may be war ranted based on inconsistencies across studies. For example, a recent study reported that depressive episodes were not as sociated with increased KP metabolites in medicationfree patients with major depressive disorder (MDD). 46 At the same time, a functional imaging study reported increased microglial activation in the PFC and ACC in patients with MDD after a depressive episode. 55 An interpretation of these apparently contradictory results is that the absence of KP ac tivation may indicate an alternative microglial activation pro cess, which likely reflects dysfunction and dystrophy in de pression, as shown in studies of rats and mice that developed depressivelike behaviour. 56 Two recent postmortem studies showed that microglial abnormalities in individuals with MDD were restricted to the neurovascular interface, 57, 58 with no evidence of M1 activation in the brain parenchyma. Our histopathological results also indicated the absence of an M1 inflammatory process in the parenchyma of the brain. Never theless, our approach using NiDAB for signal enhancement, although effective in detecting amoeboid microglia in the pa renchyma, did not allow an adequate quantification of abnor malities at the perivascular and meningeal spaces. Delineat ing whether microglial activation in depression is part of a detrimental proinflammatory process or a compensatory mechanism leading to dystrophy may help identify specific depression phenotypes associated with high versus low in flammatory biomarkers.
Limitations
Although the brain donors were wellmatched demograph ically and tissue characteristics were uniform in relevant cate gories, the present results must be considered within the limi tations of studies using postmortem human brain tissue, in which gene expression and metabolites may represent end points of pathological processes. Moreover, conclusions de rived from the analysis of a single brain region do not neces sarily extend to other brain areas, such as the ACC or the amygdala, which are also involved in the pathophysiology of depression. This study involved conducting a large number of hypothesis tests, raising the possibility of falsepositive find ings of group differences due to chance. The group differ ences we found were in the direction of higher KP activity and cytokine expression in the control group rather than the depressed group, the reverse of the directional differences we expected to find, possibly limiting concern about false positive results in our data. We attempted to address some potential confounders in exploratory subgroup analyses, J Psychiatry Neurosci which, while lacking power, showed very similar patterns in differences (or lack thereof) between depressed individuals and controls across subgroups. Information on antidepressants and other psychotropic medications was insufficient for use in the present study. While we attempted to overcome this limitation by evaluating the effects of the common antidepressant fluox etine on KP metabolites in rats, different classes of antidepres sant medications may have affected the present results. [59] [60] [61] Other variables known to affect inflammatory markers, such as body mass index, were not available for statistical corrections. While our histopathological analysis revealed no major signs of activated M1 amoeboid microglia, other microglial abnormal ities, particularly at the neurovascular interface, could not be adequately quantified in the present study.
Conclusion
In the absence of an overt inflammatory process, medical illness and/or immunotherapy, KP metabolism in the VLPFC of depressed individuals compared with non psychiatric controls is hypoactive. This effect was paralleled by reduced expression of several cytokines that strongly correlated with several components of the KP in both controls and depressed individuals. The present study reinforces the notion that depression is a highly hetero geneous condition and highlights the importance of further studies, which may lead to a more personalized pharma cotherapy for the treatment of this disorder.
